Fiche publication


Date publication

mai 2013

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier , Pr BORG Christophe , Dr GODET Yann , Dr GALAINE Jeanne


Tous les auteurs :
Adotevi O, Dosset M, Galaine J, Beziaud L, Godet Y, Borg C

Résumé

Current cancer immunotherapies predominantly rely on CD8(+) T cells to fight against tumors. However accumulative evidence showed that proinflammatory CD4(+) helper T cells are critical determinants of effective antitumor immunity. The utilization of universal tumor-reactive helper peptides from telomerase represents a powerful approach to the fully use of CD4(+) T cell-based immunotherapy.

Référence

Hum Vaccin Immunother. 2013 May;9(5):1073-7